Healthcare products manufacturer and distributor
Appears in 1 story
IPO closed with full exercise of the underwriters’ option; now trading as MDLN with proceeds allocated across debt repayment, corporate purposes, and pre-IPO equity interest redemptions.
Medline’s Nasdaq arrival as MDLN quickly turned from “biggest IPO of 2025” into a live market verdict: shares jumped roughly 41% in their first session, pushing the company into a roughly $50B+ valuation conversation almost immediately.
Updated Dec 20, 2025
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
